JCR Pharmaceuticals

JCR Pharmaceuticals
Japanese biopharmaceutical company developing biologics and gene therapies for CNS and rare diseases.
About
What does JCR Pharmaceuticals do?
JCR Pharmaceuticals Co., Ltd. is a publicly listed Japanese biopharmaceutical company founded in 1975, headquartered in Ashiya, Hyogo. It develops and commercializes biologics and gene therapies for central nervous system and rare diseases, including enzyme replacement therapies and proprietary JUST-AAV gene therapy capsids licensed to partners including Alexion.
Where is JCR Pharmaceuticals headquartered?
JCR Pharmaceuticals is headquartered in Ashiya, Japan.
When was JCR Pharmaceuticals founded?
JCR Pharmaceuticals was founded in 1975.
What industry does JCR Pharmaceuticals operate in?
JCR Pharmaceuticals operates in Biotech, Pharmaceuticals, Gene Therapy.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
AI-powered platform for personalized health and longevity.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.